Progression-free survival as endpoint in metastatic RCC?

The Lancet

Volumn 372, Issue 9637, 2008, Pages 427-429

  Knox, Jennifer J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MEDROXYPROGESTERONE; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG TARGETING; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 48649087700     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61040-5     Document Type: Note

References (13)

1. Motzer R.J., Escudier B., Oudard S., et al., for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 10.1016/S0140-6736(08)61039-9 published online July 23.
2. Motzer R.J., Hutson T.E., Tomezak P., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
3. Escudier B., Eisen T., Stadler W.M., et al., for the TARGET study group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356 (2007) 123-134
4. Johnson J.R., Williams G., and Pazdur R. Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
5. Pignatti F., Aronsson B., Vamvakas S., et al. Clinical trials for registration in the European union: the EMEA 5-year experience in oncology. Crit Rev Oncol/Hematol 42 (2002) 123-135
6. Bast R.C., Thigpen J.T., Arbuck S.G., et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107 (2007) 173-176
7. Sargent D.J., Wieand A.S., Haller D.G., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20898 patients on 18 randomised trials. J Clin Oncol 23 (2005) 8864-8870
8. Ng R., Pond G.R., Tang P.A., et al. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966-2006. Ann Oncol 19 (2008) 482-486
9. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25 suppl 18 (2007) 5023 (abstr).
10. Figlin R.A., Hutson T.E., Tomczac P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 suppl May 20 (2008) 5024 (abstr).
11. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356 (2007) 2271-2281
12. Escudier B., Pluzanska A., Korlewski P., et al., for the AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
13. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic RCC of intermediate prognosis. Cancer 110 (2007) 2468-2477